Day: February 1, 2024

Stockholm, Sweden, February 01, 2024 TWELVE MONTHS 2023Annual Recurring Revenue (ARR), including long-term service contracts, increased to MSEK 57.4 during the period, up 11% from Q4 2022. Revenue for the twelve months of 2023 was MSEK 57.0, an increase of 19.7% compared to the twelve months of 2022. Profit after tax for the twelve months of 2023 amounted to MSEK -34.3 (-49.6). Earnings per share for the twelve months of 2023 amounted to SEK -1.11 (-10.83)The complete version of the Interim Report for January – December 2023 is attached in this press release and is available on Hoylu’s web site (www.hoylu.com/investor-relations/financial-reports/). For more information, please contact:Truls Baklid, CEO, +47 924 38 900 Email: tob@hoylu.comKjartan Berge Steinshamn, CFO at Hoylu +47 481 27 673 Email: kbs@hoylu.com About Hoylu...

Another strong year as positive momentum continues LONDON, February 1, 2024 – Stolt-Nielsen Limited (Oslo Børs ticker: SNI) today reported unaudited results for the fourth quarter and full year ending November 30, 2023. The Company reported a fourth-quarter net profit of $98.4 million with revenue of $695.2 million, compared with a net profit of $95.3 million, with revenue of $732.5 million, in the fourth quarter of 2022. The net profit for the full year 2023 was $296.7 million, with revenue of $2,820.2 million, compared with a net profit of $280.9 million, with revenue of $2,771.8 million, in 2022. Highlights for the fourth quarter of 2023, compared with the fourth quarter of 2022, were:Stolt-Nielsen Limited (SNL) consolidated EBITDA1 of $208.4 million, up from $197.8 million. Earnings per share in the fourth quarter was $1.84, up...

CARGOTEC CORPORATION, INSIDE INFORMATION, 1 FEBRUARY 2024 AT 9:05 AM (EET) Inside information: The Board of Directors of Cargotec has approved a demerger plan concerning the separation of Kalmar into a new listed company HighlightsCargotec’s Board of Directors has approved a demerger plan concerning the separation of Kalmar into an independent listed company. The Demerger is subject to approval by the AGM of Cargotec to be held on 30 May 2024. The planned completion date of the Demerger is 30 June 2024. The demerger and listing prospectus, which is expected to be published by Cargotec in May 2024 before the AGM, will contain more detailed information on the Demerger and Kalmar. Certain major shareholders of Cargotec have indicated their support for the proposed Demerger.The Board of Directors of Cargotec Corporation...

CARGOTEC CORPORATION, STOCK EXCHANGE RELEASE, 1 FEBRUARY 2024 AT 9:04 AM EET Changes in Cargotec leadership team  As part of the planned separation of Kalmar by partial demerger, announced on 27 April 2023, Carina Geber-Teir, Cargotec’s SVP Communications, has been appointed as Head of Investor Relations and Communications of Kalmar. She will start in her new role on 1 April 2024 and join the Kalmar leadership team, after which, she will no longer be a member of Cargotec’s leadership team.  Cargotec previously announced on 9 November 2023 that Sami Niiranen had been appointed as President of Kalmar and proposed as the new CEO of the potential separately listed standalone Kalmar. He will start as President of Kalmar on 1 April 2024 and join Cargotec’s leadership team. As a result of these changes, Cargotec leadership team will,...

Genflow Biosciences Plc (“Genflow” or “the Company”) LONDON, Feb. 01, 2024 (GLOBE NEWSWIRE) — The Company (LSE:GENF) (OTCQB:GENFF), an emerging leader in the field of longevity research developing therapeutics that potentially halt or slow the ageing process, is pleased to provide a year-end review and summary of its progress during 2023 and defined strategic priorities for 2024. The Company achieved many significant accomplishments throughout the year across all aspects of its business. The full year-end review can be viewed on Genflow’s website: https://genflowbio.com/genflow-biosciences-plc-2023-year-in-review/. Key 2023 Highlights:Genflow expanded its intellectual property portfolio with a provisional patent application for editing the SIRT6 gene, linked to longevity and age-related diseases.Began...

LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director. Mr. Austwick brings a wealth of strategic and operational experience in the biopharmaceutical industry including more than 15 years of respiratory expertise in leadership roles across the US, China, Europe and Japan. Most recently, he served as CEO at Vectura, and previously as Nordic General Manager and Head of the Global Respiratory Franchise at Novartis and as Head of US Respiratory and Vice President Global Inhaled Respiratory at AstraZeneca. Mr. Austwick has led the development and commercialization of more than 10 brands, covering inhaled and biologic assets at a country and global level. He has an MSc in Information Management...